Veeva Systems Inc. Share Price Target ‘$241.47’, now 14.8% Upside Potential

DirectorsTalk Interviews

Veeva Systems Inc. which can be found using ticker (VEEV) now have 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $270.00 and $200.00 calculating the average target share price we see $241.47. (at the time of writing). Now with the previous closing price of $210.27 this would imply there is now a potential upside of 14.8%. The day 50 moving average is $213.11 and the 200 day moving average is $202.61. The market capitalization for the company is 33.93B. The current share price for the company is: $209.96 USD

The potential market cap would be $38,967,399,440 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 65.41, revenue per share of $14.72 and a 5.01% return on assets.

Veeva Systems Inc. is a provider of industry cloud solutions for the global life sciences industry. The Company’s offerings span cloud software, data, and business consulting and are designed to meet the needs of its customers and their most strategic business functions from research and development (R&D) to commercialization. The Company’s industry cloud solutions for the life sciences industry are grouped into two major product families: Veeva Development Cloud and Veeva Commercial Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its proprietary Veeva Vault platform. Veeva Commercial Cloud includes solutions for the sales, medical affairs, and marketing functions of a life sciences company. Its software offerings include Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix. Its data offerings include Veeva OpenData, Veeva Link, and Veeva Compass.

Share on:
Find more news, interviews, share price & company profile here for:

    CLO income fund Volta Finance delivers 0.4% return in June, NAV at €7.46

    In June 2025, Volta Finance achieved a net performance of +0.4%, lifting its cumulative return since August 2024 to +11.2%, with both CLO debt and equity assets posting gains amid easing trade tensions and stable credit markets, and ending the month with a NAV of €7.46 per share.

    Thor Energy signs term sheet with Met1 for US project sale

    Thor Energy has agreed a term sheet to sell 75% of its US uranium and vanadium subsidiaries to Met1 for a £100,000 exclusivity fee and £1 million in stock, retaining a 25% interest.

    Global Opportunities Trust NAV at £110.7 m

    As at 30 June 2025, Global Opportunities Trust reported net assets of £110.7 m with equity investments representing 64.6 % of the portfolio. Top holdings include the AVI Japanese Special Situations Fund (12.9 %) and Volunteer Park Capital Fund (7.0 %).

    China-focussed UK stock FCSS reports 27% annual share price rise

    China’s stimulus drove economic recovery, with stock selection in Hesai Group, LexinFintech and VNET adding value despite underweights in Xiaomi, Xpeng and Tuhu, while over the 12 months to 30 June 2025 the Trust’s NAV rose 28.0% and its share price gained 27.3%, outperforming the reference index’s 23.4%.

    UK market a ‘rich pool of investment opportunities’, FSV Factsheet

    UK equities delivered modest gains in June, supported by prospects of BoE rate cuts and a more constructive tariff outlook, despite a mid‑month risk‑off following US and Israel strikes on Iranian sites and subsequent relief from a ceasefire.

    Fidelity Asian Values significantly outperforms its index over 1 year (LON:FAS)

    Over the 12 months to 30 June 2025, the Trust’s NAV rose 4.9%, outperforming its reference index which fell 0.1%, while the share price gained 6.9%. Stock selection was the key driver, with contrarian positions in China and Australia and picks in materials and consumer staples adding value, though an overweight in Indonesian small caps detracted.

      Search

      Search